Wild-type and mutated IDH1/2 enzymes and therapy responses
- PMID: 29367755
- PMCID: PMC5895605
- DOI: 10.1038/s41388-017-0077-z
Wild-type and mutated IDH1/2 enzymes and therapy responses
Erratum in
-
Correction: Wild-type and mutated IDH1/2 enzymes and therapy responses.Oncogene. 2018 Oct;37(43):5810. doi: 10.1038/s41388-018-0455-1. Oncogene. 2018. PMID: 30140044 Free PMC article.
Abstract
Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the development and/or progression of various types of cancer due to supraphysiological production of D-2-hydroxyglutarate. In various tumor types, IDH1/2-mutated cancers predict for improved responses to treatment with irradiation or chemotherapy. The present review discusses the molecular basis of the sensitivity of IDH1/2-mutated cancers with respect to the function of mutated IDH1/2 in cellular processes and their interactions with novel IDH1/2-mutant inhibitors. Finally, lessons learned from IDH1/2 mutations for future clinical applications in IDH1/2 wild-type cancers are discussed.
Conflict of interest statement
J.P.M. has received honoraria, has performed consultancy, and has served as a speaker on behalf of Celgene. The remaining authors declare that they have no competing interests.
Figures
Similar articles
-
Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.Cancer Res. 2015 Nov 15;75(22):4790-802. doi: 10.1158/0008-5472.CAN-14-3603. Epub 2015 Sep 11. Cancer Res. 2015. PMID: 26363012
-
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.Cancer Res. 2013 Jan 15;73(2):496-501. doi: 10.1158/0008-5472.CAN-12-2852. Epub 2012 Nov 30. Cancer Res. 2013. PMID: 23204232 Free PMC article.
-
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.Neuro Oncol. 2013 Sep;15(9):1114-26. doi: 10.1093/neuonc/not087. Epub 2013 Jul 21. Neuro Oncol. 2013. PMID: 23877318 Free PMC article. Review.
-
RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer.Mol Cancer Res. 2019 Feb;17(2):508-520. doi: 10.1158/1541-7786.MCR-18-0557. Epub 2018 Sep 28. Mol Cancer Res. 2019. PMID: 30266754 Free PMC article.
-
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.J Natl Cancer Inst. 2010 Jul 7;102(13):932-41. doi: 10.1093/jnci/djq187. Epub 2010 May 31. J Natl Cancer Inst. 2010. PMID: 20513808 Free PMC article. Review.
Cited by
-
IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF-κB signaling to promote colorectal cancer progression.Cell Oncol (Dordr). 2023 Feb;46(1):145-164. doi: 10.1007/s13402-022-00740-2. Epub 2022 Nov 19. Cell Oncol (Dordr). 2023. PMID: 36401762
-
Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma.Virchows Arch. 2020 Jan;476(1):135-146. doi: 10.1007/s00428-019-02699-2. Epub 2019 Nov 14. Virchows Arch. 2020. PMID: 31728625 Free PMC article. Review.
-
Biliary tract cancer prognostic and predictive genomics.Chin Clin Oncol. 2019 Aug;8(4):42. doi: 10.21037/cco.2019.07.06. Epub 2019 Jul 29. Chin Clin Oncol. 2019. PMID: 31431036 Free PMC article.
-
Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review.Cureus. 2022 Jun 23;14(6):e26233. doi: 10.7759/cureus.26233. eCollection 2022 Jun. Cureus. 2022. PMID: 35911272 Free PMC article. Review.
-
Translation of Precision Medicine Research Into Biomarker-Informed Care in Radiation Oncology.Semin Radiat Oncol. 2022 Jan;32(1):42-53. doi: 10.1016/j.semradonc.2021.09.001. Semin Radiat Oncol. 2022. PMID: 34861995 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous